The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Andrew Tsai - Jefferies Financial Group Inc. - Analyst
: Hey. Thanks, good morning, and congratulations on the execution of the launch. Thanks for taking my question. So the first one is as we tweak
around our models, what kind of payer rejection and patient abandonment rate should we be modeling for ensifentrine? And can you remind us
if there will be free drug? Thanks.
Question: Andrew Tsai - Jefferies Financial Group Inc. - Analyst
: No -- yes. And secondly, consensus for Q3 is $1.5 million. If we assumed patients who get reimbursed this quarter maybe get treated for an average
of half a month, then by my calculation, the number of patients needed is 1,400 or more. Would you feel comfortable meeting or exceeding that
patient number in Q3 or exiting out of September 30? Thanks.
Question: Andrew Tsai - Jefferies Financial Group Inc. - Analyst
: Okay, great. Thank you.
Question: Emma Nesson - Piper Sandler Companies - Analyst
: Hi. This is Emma on for Yas. Thanks for taking our questions. Firstly, do you provide any color on patient starting forms and how that ties into how
you're thinking about patient uptake? And with that, what type of metrics do you plan to share at next earnings in November to help us track the
launch progress and guide future expectations?
Question: Tom Shrader - BTIG, LLC - Analyst
: Good morning and congratulations. I have what's probably an annoying question, but you've written 100 prescriptions. Do you have any read on
who they're for? Or are they all patients unhappy on triple, or are you already seeing people try the drug earlier?
Question: Tom Shrader - BTIG, LLC - Analyst
: Okay. And then a quick question on the fixed dose. To try a fixed dose in a handheld device, do you have to get the monotherapy approved in a
handheld device first? Or could you in fact try that combination in a different device?
Question: Tom Shrader - BTIG, LLC - Analyst
: Got it. Okay. Thank you very much.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 1:00PM, VRNA.OQ - Q2 2024 Verona Pharma PLC Earnings Call
Question: Jing Deng - Truist Securities - Analyst
: Hi. Thank you. This is Jing for Joon, and thanks for taking my questions. And also, congratulations on your progress. So I have other questions
regarding about your -- can you give more color on the drug compared with treating the non-CF bronchiectasis, especially compared with your
competitors like [EnziMed], [Preventol], (inaudible)? And then also could you give some -- provide some unique -- this mechanism for this drug can
be offered better, a competitive edge over other drugs. Thanks.
Question: Jing Deng - Truist Securities - Analyst
: Great, thanks. But do you have any pre-clinical data to support what you have for this indication?
Question: Jing Deng - Truist Securities - Analyst
: Okay, thank you so much. Thanks for taking my questions.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 1:00PM, VRNA.OQ - Q2 2024 Verona Pharma PLC Earnings Call
Question: Ram Selvaraju - H.C. Wainwright & Co., LLC - Analyst
: Thanks very much for taking my questions. On the commercial front, this is probably for Chris, I wanted to see if you could provide us with some
more granularity on what you are currently engaged in doing on the social media front and what you plan to do in the course of the coming months
with respect to marketing outreach and also when you anticipate involving direct-to-consumer advertising as part of the overall commercial process
for Ohtuvayre?
And if so, what forms that might potentially take? And what you might think about doing on, for example, the speaker program side with physicians,
as well as what you're seeing in terms of patient advocacy involvement in support of Ohtuvayre within the COPD community?
Question: Ram Selvaraju - H.C. Wainwright & Co., LLC - Analyst
: And then, just very quickly on the non-CF bronchiectasis, I was wondering if you could give us some additional color on the timeline to reach full
enrollment and potentially the timeline to data, or if you don't have that great a read on that yet?
Question: Ram Selvaraju - H.C. Wainwright & Co., LLC - Analyst
: Thank you.
Question: Edward Thomason - Kempen Capital Management N.V. - Analyst
: Good afternoon, good morning, and thanks for taking my question. I had a quick question just about the pricing. In recent weeks, we've seen news
how the pricing differences -- this is from the ICR cost-effective pricing on an annual basis. Does that have any implications on reimbursement, and
how does that play into your strategy for the Ohtuvayre launch?
Question: Edward Thomason - Kempen Capital Management N.V. - Analyst
: Okay. Thank you. And then I just had a follow-up question actually on the data that we might be expecting at ERS and CHEST later in the year. Can
you just give us a flavor on what we might expect from those releases, whether that will be subgroup analysis or patient populations or background
therapies, just so we can whet the appetite ahead of that?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 1:00PM, VRNA.OQ - Q2 2024 Verona Pharma PLC Earnings Call
Question: Edward Thomason - Kempen Capital Management N.V. - Analyst
: That's very clear. Thank you very much.
| 
